Ruxolitinib

Opzelura achieved significant efficacy for the treatment of atopic dermatitis in children aged as young as 2 years, Incyte announced in a press release.

The FDA approved momelotinib for treatment of patients with myelofibrosis and anemia regardless of prior myelofibrosis therapy.

A phase 2 trial of axatilimab for chronic graft-versus-host disease met its primary endpoint, according to the agent’s manufacturer.

Researchers created a comprehensive guide about the pharmacology, efficacy, safety and patient cost options of topical ruxolitinib for the treatment of nonsegmental vitiligo.

In this video, Ruben Mesa, MD, discussed the backstory behind a study presented at ASCO Annual Meeting, examining the effect of luspatercept on patients with myelofibrosis suffering from anemia.

In this video, Idoroenyi Amanam, MD, discussed a study presented at ASCO Annual Meeting, that looked an ALK2 inhibitor along with ruxolitinib in the treatment of anemia in myelofibrosis.

New data from a phase 2 study evaluating the short-term clinical benefits of Opzelura cream 1.5% showed a reduction in itch among adults with mild to moderate atopic dermatitis, Incyte announced in a press release.

A randomized phase 3 study of parsaclisib plus ruxolitinib for adults with myelofibrosis appeared unlikely to meet its primary endpoint and will be discontinued, according to the agents’ manufacturer.

Chronic graft-versus-host disease continues to be a leading cause of late morbidity and mortality, complicating approximately 35% to 50% of allogeneic transplantations.

Treatment with ruxolitinib cream was well tolerated and effective with no effect on blood counts or bone growth among children with atopic dermatitis, according to a study published in Annals of Allergy, Asthma & Immunology.